Login to Your Account



Clinic Roundup


Monday, May 13, 2013
• Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, said it is progressing into the placebo-controlled portion of its Phase II trial of LX4211 in patients with Type I diabetes after identifying the once-daily 400-mg dose as the appropriate treatment for the expansion phase of the trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription